%49 gain on $CTIC : CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19
Download Preticks mobile app to know the news first 🚀
#StockMarket #stocks #StocksToTrade https://t.co/eRthYsllj2